OS Therapies Incorporated Common Stock (OSTX)

FairStock Score: 13/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I come to OS Therapies wearing Graham's skeptic's hat. The company is a clinical-stage biopharmaceutical firm with two pipeline candidates, OST-HER2 and OST-tADC, and just four employees. It has no revenue in the filed statements. The losses are real: in fiscal 2025, the year ended 2025-12-31, net income was -$28.8 million; in fiscal 2024, the year ended 2024-12-31, it was -$8.9 million; and in fiscal 2023, the year ended 2023-12-31, it was -$7.8 million. The first half of fiscal 2026 was no better: fiscal Q1 2026, the quarter ended 2026-03-31, lost $10.4 million, and fiscal Q2 2026, the quarter ended 2026-06-30, lost $8.6 million. Trailing free cash flow is -$18.5 million, a -27.7% FCF yield against the $66.9 million market cap. At the close on 2026-10-13, the price was $1.45, with a FairStock P/E calculation of -1.34 and EPS of -$1.08. FairStock's metrics underscore fragility: Piotroski 1/9, Altman Z-Score -12.42, and FairStock Score 13/100. The Lynch category is none because the company has lost money in each of the last three years. There is no visible moat to me: no commercial product, no revenue, no profits. The value, if any, lies in future clinical success, not present earning power. That is a speculative proposition. A negative beta of -0.64 may look diversifying, but it does not substitute for solvency or cash generation.

In plain English: OS Therapies is a small clinical-stage drug company trying to develop treatments for bone cancer and other solid tumors. It has no product sales yet and is losing money, with losses and cash burn worsening in the latest filed periods. At $1.45 on 2026-10-13, the price does not look cheap or expensive based on ordinary profits, because there are no profits; it is a speculative bet on future trial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer